Research programme: HCV and HIV polymerase inhibitors - RocheAlternative Names: RO-0622; RO-9187
Latest Information Update: 06 May 2009
At a glance
- Originator Roche
- Class Deoxyribonucleosides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hepatitis C; HIV-1 infections